Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MPM Raises $400m To Build Early-Stage Biotechs

Executive Summary

The venture capitalist builds biotechs from scratch and with this latest fund, MPM is looking to add to its sector-leading record of 49 FDA-approved drugs and over 100 IPOs and acquisitions.

You may also be interested in...



Astellas Exercises Option To Acquire Potenza, For Up To $405m

Astellas has exercised an option to acquire Potenza, paying up to $404.7m in cash for the private US venture in a deal that will boost its presence in immuno-oncology.

Boehringer Pledges Another €30m To Tackle AMR

The three companies have joined forces to launch Aurobac Therapeutics, combining their respective strengths to develop a precision approach to treating infections.

Destiny Pharma Sees Potential For XF-73 In Oral Mucositis

A new research program exploring an additional indication for XF-73 will help the UK biotech's licensing discussions for the nasal gel.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC124706

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel